PRNewsWire
11 Jun 2026, 07:27 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The lawsuit claims Zoetis made false and misleading statements regarding challenges facing its Librela, Apoquel, and Cytopoint product lines. — Allegations of product-line failures in core offerings suggest fundamental business headwinds that could impact future revenue growth.
-0.50Zoetis Inc. (ZTS) is facing a class action lawsuit alleging violations of the Securities Exchange Act and Rule 10b-5. — Securities litigation creates legal uncertainty and potential financial liabilities, typically weighing on a company's stock price.
-0.40Which stocks this story touches
The company is being sued for securities law violations in a class action lawsuit.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit alleging false and misleading statements regarding product line challenges.
The company is being sued for securities law violations in a class action lawsuit.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
PRNewsWire
5h ago
